<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        149-186-01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2001
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        NEGAZOLE 500MG TAB.
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        METRONIDAZOLE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        12.05
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Gulf Pharmaceutical Industries (Julphar)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Gulf Pharmaceutical Industries (Julphar)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Gulf Pharmaceutical Industries (Julphar)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        P01AB01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Negazole </strong>is an antibacterial and antiparasitic antibiotic belonging to the 5-nitroimidazole group of medicines.</p><p>This medicine is used to treat certain infections caused by bacteria or parasites that are sensitive to <strong>Negazole.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not Negazole if:</strong></p><p>&bull; You are allergic to metronidazole, to any medicine in the imidazole group (the group of antibiotics that includes<br />&nbsp;&nbsp; metronidazole) or any of the other ingredients of this medicine listed in Section 6,</p><p>&bull; The patient is a child under 6 years of age (see Warnings and precautions).</p><p>Appropriate precautions for use; special warnings</p><p><strong>Warnings and precautions</strong></p><p>Before taking <strong>Negazole,</strong> tell your doctor if:</p><p>&bull; you have severe, chronic or progressive nervous disorders,</p><p>&bull; you have psychiatric disorders,</p><p>&bull; you have blood disorders,</p><p>&bull; you have ever had meningitis under metronidazole treatment.</p><p>Tell your doctor immediately if any of the following problems occur during treatment with <strong>Negazole</strong></p><p>From the very first doses there is a risk of severe and sudden allergic reaction (anaphylactic shock, angioedema) possibly causing the following symptoms: tight chest, dizziness, nausea or fainting, or dizziness when standing up (see &quot;Possible side effects&quot;). This can occur as soon as you begin taking the medicine. If these symptoms occur, stop using this medicine because your life might be in danger, and immediately contact your doctor.</p><p>If, at the start of treatment, you observe redness all over the body with pustules, accompanied by fever, a serious reaction known as acute generalized exanthematous pustulosis should be suspected (see &quot;Possible side effects&quot;). Inform your doctor immediately, as treatment must be stopped. If such a reaction occurs, you should never again take metronidazole alone or in combination with another active substance in the same medicine.</p><p>You should watch out for any potential signs or worsening of nervous disorders such as difficulty coordinating movements, dizziness, confusion, seizures, difficulty speaking or walking, shakiness, involuntary eye movements, as well as other effects on the hands and feet such as tingling, pins and needles, feeling cold, numbness and reduced sense of touch. These disorders are generally reversible on stopping treatment. It is therefore important to stop taking this medicine and see a doctor immediately (see &quot;Possible side effects&quot;).</p><p>From the very first doses of treatment, your behavior may alter and put you at risk, especially if you have had psychiatric problems in the past. If this happens, you should stop taking the medicine and see a doctor (see &quot;Possible side effects&quot;).</p><p>If you have had blood disorders in the past, or are receiving high-dose and/or long-term treatment, your doctor may prescribe regular blood tests to check your complete blood count.</p><p>Inform the doctor or analysis laboratory that you are taking this medicine if you have to have a medical laboratory test, as taking metronidazole may interfere with some laboratory test results (test for treponema) by triggering a false positive result for a test (e.g. the Nelson test).</p><p>Cases of severe hepatotoxicity/acute liver failure, including cases with a fatal outcome in patients with Cockayne syndrome, have been reported with medicines containing metronidazole.</p><p>If you have Cockayne syndrome, your doctor must monitor your liver function frequently, both during and after your treatment with metronidazole.</p><p><strong>Tell your doctor immediately and stop taking metronidazole if you have the following symptoms:</strong></p><p>&bull; stomach ache, anorexia, nausea, vomiting, fever, feeling faint, tiredness, jaundice, dark-colored urine, putty-<br />&nbsp;&nbsp; colored stools or itching.</p><p><strong>Children</strong></p><p>The tablets must not be given to children under 6 years of age due to the risk of choking. Other dosage forms of this antibiotic are available for young children.</p><p>Talk to your doctor or pharmacist before taking <strong>Negazole</strong>.</p><p><strong>Other medicines and Negazole</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Tell your doctor if you are taking:</p><p>&bull; medicines containing alcohol because of the risk of side effects such as redness of the face, feeling hot,<br />&nbsp;&nbsp; vomiting and increased heart rate,</p><p>&bull; busulfan (recommended for the treatment of certain types of blood disorders and for the preparation of a bone<br />&nbsp;&nbsp; marrow transplant),</p><p>&bull; disulfiram (used to prevent relapse in alcohol-dependent patients).</p><p><strong>Negazole with food and drink</strong></p><p>You should avoid drinking alcohol while taking this medicine due to the risk of side effects such as redness of the face, feeling hot, vomiting and increased heart rate.</p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>If necessary, this medicine may be used during pregnancy. However, you must always ask your doctor or pharmacist for advice before taking it.</p><p>You should avoid breast-feeding while taking this medicine.</p><p><strong>Driving and using machines</strong></p><p>You should be aware, particularly if you drive or use machines, that there is a risk of dizziness, confusion, hallucinations, seizures and vision disorders associated with this medicine.</p><p><strong>Important information about some of the ingredients of Negazole</strong><strong>:</strong></p><p>This medicine contains lactose. If you have been told by your doctor that you are intolerance to some sugars, contact your doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Dosage</strong></p><p>This medicine is for adults and children at least 6 years of age only. More suitable dosage forms are available for children under 6 years of age. The dosage depends on your age and the illness being treated.</p><p>As an indication, the usual dose is:</p><p><strong><u>Negazole 250mg Tablets:</u></strong></p><p>&sect; Adults: 0.50 g/day to 1.5 g/day.</p><p>&sect; Children: 375 mg/day - 20 to 40 mg/kg/day.</p><p><strong>How often should be taken:</strong> 2 to 3 times a day depending on why you are taking this medicine.</p><p><strong><u>Negazole 500mg Tablets:</u></strong></p><p>&sect; Adults: 0.750 g/day to 2 g/day.</p><p>&sect; Children: 500 mg/day to 20-40 mg/kg/day.</p><p><strong>How often should be taken:</strong> 1 to 3 times a day depending on why you are taking this medicine.</p><p>In some cases, it is essential that your partner be treated, whether or not he/she has any clinical signs.</p><p><strong>In all cases, follow your doctor&#39;s prescription.</strong></p><p><strong>How Negazole should be taken</strong></p><p>&sect; Oral use.</p><p>Swallow the tablets with a glass of water.</p><p><strong>How long Negazole should be used for</strong></p><p>In order to be effective, this antibiotic must be used regularly at the prescribed doses and for as long as your doctor advises.</p><p>If your fever or any other symptom disappears, it does not mean that you are cured. If you feel tired, this is not due to the antibiotic treatment but to the infection itself. Reducing or stopping your treatment would have no effect on this feeling and would only delay your recovery.</p><p>Special cases: treatment of giardiasis (infection caused by a parasite) should last 5 days, treatment of amebiasis (infection caused by a parasite) and some types of vaginitis (infection of the vagina), 7 days and treatment of trichomoniasis (infection caused by a parasite) is a single-dose treatment.</p><p>I<strong>f you take more Negazole than you should</strong></p><p>Consult your doctor or pharmacist immediately.</p><p>If you are vomiting, have difficulty coordinating your movements or are disorientated, consult your doctor. Your doctor may decide to prescribe appropriate treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>Digestive disorders</strong></p><p>&bull; digestive disorders that are not serious, such as stomach ache, nausea, vomiting, diarrhea,</p><p>&bull; inflammation of the tongue and dry mouth, inflammation of the mouth, taste disorders, loss of appetite,</p><p>&bull; pancreatitis (inflammation of the pancreas), which is reversible after stopping treatment,</p><p>&bull; discoloration or change in the appearance of the tongue (may be caused by fungal growth).</p><p><strong>Effects on the skin and mucous membranes</strong></p><p>&bull; hot flushes with redness of the face, itching, skin rashes sometimes accompanied by fever,</p><p>&bull; hives (skin rash similar to nettle rash), sudden allergic swelling of the face and neck (angioedema), allergic<br />&nbsp;&nbsp; shock which could be life-threatening (see &quot; before you take <strong>Negazole</strong>&quot;),</p><p>&bull; very rare cases of redness spreading to the whole body with pustules, accompanied by fever (acute<br />&nbsp;&nbsp;&nbsp; generalized exanthematous pustulosis) (see &quot;before you take <strong>Negazole</strong> &quot;),</p><p>&bull; a blistering rash with peeling of the skin which can spread to the whole body and be life-threatening (toxic<br />&nbsp; epidermal necrolysis, Stevens-Johnson syndrome),</p><p>&bull; fixed drug eruption: round, red patches of skin rash with an itchy, burning sensation leaving colored marks and<br />&nbsp; possibly reappearing in the same places if treatment is resumed with the same medicine.</p><p><strong>Nervous system disorders</strong></p><p>&bull; nerve damage in the limbs (peripheral sensory neuropathy) with effects on the hands and feet such as tingling,<br />&nbsp;&nbsp;pins and needles, feeling cold, numbness and reduced sense of touch,</p><p>&bull; headache,</p><p>&bull; dizziness,</p><p>&bull; seizures,</p><p>&bull; confusion,</p><p>&bull; neurological disorders, known as encephalopathy or cerebellar syndrome, with symptoms including confusion,<br />&nbsp; consciousness disorders, behavioral disorders, difficulty coordinating movements, problems with pronunciation,<br />&nbsp; gait disorders, involuntary eye movements, shakiness. These disorders are generally reversible on stopping<br />&nbsp; treatment and may be associated with changes in MRI scans. Very rare cases of fatal outcome have been<br />&nbsp; reported (see &quot; before you take <strong>Negazole</strong> &quot;),</p><p>&bull; non-bacterial meningitis.</p><p><strong>Psychiatric disorders</strong></p><p>&bull; hallucinations,</p><p>&bull; personality disorders (paranoia, delirium) that may be accompanied by suicidal thoughts or actions (see &quot;<br />&nbsp;&nbsp; before you take <strong>Negazole</strong> &quot;),</p><p>&bull; depressive tendency.</p><p><strong>Vision disorders</strong></p><p>&bull; temporary vision disorders such as blurred vision, double vision, short-sightedness, decreased vision, changes<br />&nbsp; in color vision,</p><p>&bull; optic nerve damage/inflammation.</p><p><strong>Blood disorders</strong></p><p>&bull; abnormally low platelet counts, abnormally low or major drop in the number of certain white blood cells<br />&nbsp;&nbsp; (neutrophils).</p><p><strong>Effects on the liver</strong></p><p>&bull; elevated liver enzymes (transaminases, alkaline phosphatase),</p><p>&bull; very rare cases of serious liver disease (sometimes with jaundice), in particular cases of liver failure requiring a<br />&nbsp; transplant.</p><p><strong>Other effects</strong></p><p>&bull; reddish-brown colored urine caused by the medicine.</p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>Reporting of side effects:</u></strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible</p><p>side effects not listed in this leaflet. You can also report side effects directly via:</p><p><strong>&bull; Saudi Arabia:</strong></p><p><strong>The National Pharmacovigilance Centre (NPC):</strong></p><p><strong>- Fax: </strong>+966-11-205-7662</p><p><strong>- SFDA Call Centre: </strong>19999</p><p><strong>- E-mail: </strong>npc.drug@sfda.gov.sa</p><p><strong>- Website: </strong>https://ade.sfda.gov.sa</p><p><strong>&bull; Other GCC States:</strong></p><p><strong>- </strong>Please contact the relevant competent authority</p><p>By reporting side effects, you can help provide more information on the safety of this medicine</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>-&nbsp;&nbsp;&nbsp; Do not take <strong>Negazole</strong> after the expiry date which is stated on the carton and blister. This expiry date refers to the last day of that month.</p><p>-&nbsp;&nbsp;&nbsp; Store below 30&deg;C, in a dry place, protected from light.</p><p>-&nbsp;&nbsp;&nbsp; Do not take<strong> Negazole</strong> if you notice any visible signs of deterioration.</p><p>-&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is metronidazole. Each film-coated tablet contains 250mg or 500mg of metronidazole.</p><p>The other ingredients are: Lactose monohydrate, microcrystalline cellulose, maize starch, primojel, PVP K-30, stearic acid, magnesium stearate, hypromellose and talc.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Negazole 250mg film-coated tablets are available in packs of 20 tablets or hospital packs of 100 or 1000 tablets.
Negazole 500mg film- coated tablets are available in packs of 20 tablets or hospital packs 100 or 500 tablets.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Gulf Pharmaceutical Industries &quot; Julphar&quot;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                13/11/2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">إن <strong>نيجازول</strong> ھو مضاد حیوي مضاد للبكتیریا والطفیلیاّت وهو ینتمي إلى مجموعة الأدویة تعرف باسم 5- نیترویمیدازول.</p><p dir="RTL">يعمل <strong>نيجازول </strong>عن طريق القضاء على البكتيريا والطفيليات التي تسبب العدوى في الجسم والحساسة <strong>لنيجازول.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يجب عدم تناول نيجازول إذا كنت:</strong></p><p dir="RTL">&bull;&nbsp; تعاني من الحساسية تجاه ميترونيدازول، أو تجاه أية أدوية أخرى من مجموعة الإیمیدازول (مجموعة المضادات الحیویةّ التي تحتوي على ميترونیدازول) أو المواد الأخرى في الدواء الخاص بك (المذكورة في البند رقم 6: &quot; معلومات إضافية&quot;).</p><p dir="RTL">&bull;&nbsp; إذا كان المریض بعمر أقل من 6 سنوات (انظر &quot;تحذيرات واحتياطات&quot;).</p><p dir="RTL">تحذيرات واحتياطات خاصة للاستخدام</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">يرجى منك التحدث مع طبيبك المعالج قبل تناول <strong>نيجازول </strong>في الحالات التالية:</p><p dir="RTL">&bull;&nbsp; إذا كنت تعاني من اضطرابات عصبیّة حادة، مزمنة أو تصاعدیّة،</p><p dir="RTL">&bull;&nbsp; إذا كنت تعاني من اضطرابات نفسیّة،</p><p dir="RTL">&bull;&nbsp; إذا كنت تعاني من اضطرابات في الدم،</p><p dir="RTL">&bull;&nbsp; إذا كنت قد عانيت مسبقاً من التھاب السحایا خلال فترة العلاج باستخدام ميترونيدازول.</p><p dir="RTL">يرجى منك إخبار طبيبك المعالج على الفور في حال تعرضت لأحد المشكلات التالية خلال فترة العلاج باستخدام <strong>نيجازول</strong></p><p dir="RTL">من الجرعات العلاجية الأولية، لوحظ حدوث تفاعلات تحسسية شديدة ومفاجئة (صدمة الحساسية، وذمة وعائية) مما قد يسبب الأعراض التالية: ضيق في الصدر، دوخة، غثيان أو إغماء، أو الشعور بدوخة عند الوقوف (انظر &quot;التأثيرات الجانبية المحتمل حدوثها&quot;). قد تحدث هذه الأعراض عند البدء في تناول هذا الدواء. يرجى منك التوقف عن تناول هذا الدواء وإخبار طبيبك المعالج على الفور في حال حدوث هذه الأعراض فقد تكون مهددة للحياة.</p><p dir="RTL">يجب عليك إخبار طبيبك المعالج على الفور حيث يجب إيقاف العلاج باستخدام <strong>نيجازول</strong> في حال لاحظت في بداية العلاج حدوث احمرار في جميع أنحاء الجسم مع ظهور بثور مصحوباً بحدوث حمى، حيث يشتبه حدوث رد فعل خطير يعرف باسم البثار الطفحي الحاد المعمم (انظر &quot;التأثيرات الجانبية المحتمل حدوثها&quot;)<strong>. </strong>في حال حدوث ذلك<strong> </strong>يجب عليك عدم تناول <strong>نيجازول</strong> بمفرده أو بالتزامن مع مادة فعالة أخرى في نفس الدواء.</p><p dir="RTL">يجب عليك توخي الحذر في حال ظهور أي أعراض محتملة أو تفاقم الاضطرابات العصبية على سبيل المثال صعوبة تنسيق الحركات، الشعور بدوخة، ارتباك، نوبات، صعوبة التحدث أو المشي، رعشة، حركات العين اللاإرادية، بالإضافة إلى تأثيرات أخرى على اليدين والقدمين مثل الوخز كوخز الإبر والدبابيس، الشعور بالبرد، تنميل وانخفاض في حاسة اللمس. إن هذه الاضطرابات قد تختفي عند إيقاف العلاج. ولذلك فمن المهم التوقف عن تناول هذا الدواء ومراجعة الطبيب المعالج على الفور (انظر &quot;التأثيرات الجانبية المحتمل حدوثها&quot;).</p><p dir="RTL">قد تلاحظ تغير في السلوك عند تناول الجرعات الأولى من العلاج وقد يعرضك للخطر بشكل خاص إذا عانيت مسبقاً من مشاكل نفسية. في حال حدوث ذلك، يجب عليك التوقف عن تناول هذا الدواء ومراجعة الطبيب المعالج (انظر &quot;التأثيرات الجانبية المحتمل حدوثها&quot;).</p><p dir="RTL">إذا عانيت مسبقاً من اضطرابات في الدم، أو كنت تتلقى جرعة عالية و/أو علاجاً طويل الأمد، فقد يصف لك طبيبك المعالج القيام باختبارات دم منتظمة للتحقق من تعداد الدم الكامل.</p><p dir="RTL">يرجى منك إخبار طبيبك المعالج أو مختبر التحليل أنك تتناول هذا الدواء إذا كان عليك إجراء فحص مختبري طبي، حيث إن تناول ميترونيدازول قد يتداخل مع بعض نتائج الاختبارات (اختبار اللولبية) عن طريق ظهور نتيجة إيجابية كاذبة (مثل اختبار نيلسون).</p><p dir="RTL">سجل حدوث حالات التسمم الكبدي الشديد/ قصور كبدي حاد، بما في ذلك الحالات التي أدت إلى الوفاة لدى المرضى الذين يعانون من متلازمة كوكايين أثناء تلقي العلاج باستخدام ميترونيدازول.</p><p dir="RTL">يجب على طبيبك المعالج مراقبة وظائف الكبد لديك بشكل دوري أثناء وبعد فترة تلقي العلاج باستخدام<strong> </strong>ميترونیدازول، إذا كنت تعاني من متلازمة كوكايين.</p><p dir="RTL"><strong>يرجى منك إخبار طبيبك المعالج على الفور والتوقف عن تناول نيجازول في حال حدوث ما يلي:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; ألم في المعدة، فقدان الشهية، غثيان، تقيؤ، حمى، شعور بالإغماء، الشعور بالتعب، يرقان، بول داكن اللون، براز مصفر اللون أو حكة.</p><p dir="RTL"><strong>الأطفال</strong></p><p dir="RTL">يجب عدم إعطاء هذا الدواء للأطفال بعمر أقل من 6 سنوات<strong> </strong>بسبب خطر الاختناق. تتوفر أشكال صيدلانية أخرى من هذا الدواء الملائمة للأطفال الصغار.</p><p dir="RTL">يرجى منك التحدث مع طبيبك المعالج أو الصيدلي الذي تتعامل معه قبل تناول <strong>نيجازول</strong>.</p><p dir="RTL"><strong>تناول الأدوية الأخرى بالتزامن مع </strong><strong>نيجازول</strong></p><p dir="RTL">يرجى منك إخبار طبيبك المعالج أو الصيدلي الذي تتعامل معه إذا كنت تتناول، تناولت مؤخراً، أو قد تتناول أي أدوية أخرى. يرجى منك إخبار طبيبك المعالج إذا كنت تتناول:</p><p dir="RTL">&bull; الأدوية التي تحتوي على الكحول وذلك بسبب خطورة آثارها الجانبية مثل احمرار الوجه، الشعور بالسخونة، تقيؤ وزيادة معدل ضربات القلب.</p><p dir="RTL">&bull; بوسولفان (يوصى به لعلاج أنواع معينة من اضطرابات الدم ولتحضير عملية زراعة نخاع العظم)،</p><p dir="RTL">&bull; ديسلفيرام (يستخدم لمنع الانتكاس لدى المرضى المدمنين على الكحول).</p><p dir="RTL"><strong>تناول </strong><strong>نيجازول</strong><strong> مع الطعام والشراب</strong></p><p dir="RTL">يجب عليك تجنب شرب الكحول أثناء فترة تناول هذا الدواء بسبب خطورة الآثار الجانبية مثل احمرار الوجه، الشعور بالسخونة، تقيؤ وزيادة معدل ضربات القلب.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">يرجى منك إخبار طبيبك المعالج أو الصيدلي الذي تتعاملين معه للحصول على النصيحة قبل تناول هذا الدواء إذا كنت حاملاً أو ترضعين طفلك رضاعة طبيعية، تعتقدين أنك حاملاً أو تخططين لذلك</p><p dir="RTL">يمكن استخدام هذا الدواء أثناء الحمل عند الضرورة. ومع ذلك، يجب عليك دائماً استشارة طبيبك المعالج أو الصيدلي الذي تتعامل معه قبل تناول هذا الدواء.</p><p dir="RTL">يجب عليك تجنب الرضاعة الطبيعية أثناء فترة تناول هذا الدواء.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">يجب أن تكون على دراية، في حال القيادة أو استخدام الآلات، حيث قد يؤدي هذا الدواء إلى الشعور بدوخة، ارتباك، هلوسة، نوبات واضطرابات في الرؤية.</p><p dir="RTL"><strong>معلومات هامة عن بعض مكونات </strong><strong>نيجازول</strong></p><p dir="RTL">يحتوي هذا الدواء على اللاكتوز. يرجى منك استشارة طبيبك المعالج قبل تناول هذا الدواء إذا كان قد أخبرك مسبقاً بأنك تعاني من مشكلة تتمثل في عدم المقدرة على تحمل بعض أنواع السكر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مقدار الجرعة الواجب عليك تناولها </strong></p><p dir="RTL">يوصى باستعمال هذا الدواء من قبل البالغون والأطفال بعمر لا يقل عن 6 سنوات فقط. تتوفر أشكال صيدلانية أخرى ملائمة للأطفال بعمر أقل من 6 سنوات. يعتمد مقدار الجرعة على العمر ونوع المرض المراد علاجه.</p><p dir="RTL">وفقاً لدواعي الاستعمال، يبلغ مقدار الجرعة الاعتيادية على النحو التالي:</p><p dir="RTL"><strong><u>أقراص نيجازول 250 ملغم</u></strong></p><p dir="RTL">&bull;&nbsp; البالغون: 0,5 غرام/يوم إلى 1,5 غرام/يوم</p><p dir="RTL">&bull;&nbsp; الأطفال: 375 ملغم/يوم&nbsp; &ndash; 20 إلى 40 ملغم/كيلوغرام/يوم</p><p dir="RTL"><strong>عدد مرات تناول نيجازول </strong>: 2 إلى 3 مرات في اليوم، اعتماداً على سبب استخدام هذا الدواء.</p><p dir="RTL"><strong><u>أقراص نيجازول 500 ملغم</u></strong></p><p dir="RTL">&bull;&nbsp; البالغون: 0,750 غرام/يوم إلى 2 غرام/يوم</p><p dir="RTL">&bull;&nbsp; الأطفال: 500 ملغم/يوم&nbsp; &ndash; 20 إلى 40 ملغم/كيلوغرام/يوم</p><p dir="RTL"><strong>عدد مرات تناول نيجازول </strong>: 1 إلى 3 مرات في اليوم، اعتماداً على سبب استخدام هذا الدواء.</p><p dir="RTL">في بعض الحالات، من المهم أن يتلقى شريك حياتك العلاج سواء في حال ظهور أو عدم ظهور أية علامات سريرية لديه.</p><p dir="RTL"><strong>في جميع الحالات، يرجى منك اتباع تعليمات طبيبك المعالج.</strong></p><p dir="RTL"><strong>كيفية تناول نيجازول</strong></p><p dir="RTL">&bull;&nbsp; يستخدم هذا الدواء عن طريق الفم</p><p dir="RTL">&bull;&nbsp; قم ببلع الأقراص مع كوباً من الماء</p><p dir="RTL"><strong>مدة العلاج اللازمة باستخدام نيجازول</strong></p><p dir="RTL">للحصول على أفضل النتائج، يجب تناول هذا المضاد الحيوي بصورة منتظمة بالمقدار الموصى به للفترة الزمنية الموصى بها من قبل طبيبك المعالج.</p><p dir="RTL">لا يدل تحسن حالة الحمى أو الأعراض الأخرى على شفائك من الحالة المرضية التي تعاني منها.</p><p dir="RTL">إن الشعور بالتعب ينجم عن العدوى التي تعاني منها ولا علاقة له بتلقي العلاج باستخدام المضادات الحيوية، لذلك فإن التقليل أو التوقف عن العلاج لا يؤثر على هذا الشعور ولكن قد يتسبب في تأخير تحسن حالتك الصحية.</p><p dir="RTL">الحالات الخاصة: يتم تناول هذا الدواء لمدة لا تقل عن 5 أيام لعلاج داء الجيارديات (عدوى ناجمة عن الطفيليات)، ولمدة 7 أيام لعلاج داء الأميبات (عدوى ناجمة عن الطفيليات) وبعض أنواع حالات التهاب المهبل، وجرعة مفردة لعلاج داء المشعرات (عدوى ناجمة عن الطفيليات).</p><p dir="RTL"><strong>إذا تناولت نيجازول بجرعة أكبر مما يجب</strong></p><p dir="RTL">يرجى منك إخبار طبيبك المعالج أو الصيدلي الذي تتعامل معه على الفور إذا عانيت من تقيؤ، صعوبة في تنسيق الحركات أو تشعر بالارتباك. قد يقوم طبيبك المعالج بوصف العلاج المناسب لك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال مع جميع الأدوية، قد يسبب هذا الدواء تأثيرات جانبية، بالرغم من أنها قد لا تحدث لكل شخص.</p><p dir="RTL"><strong>اضطرابات في الجهاز الهضمي</strong></p><p dir="RTL">&bull; اضطرابات الجهاز الهضمي غير الخطيرة، مثل آلام المعدة، غثيان، تقيؤ، إسهال،</p><p dir="RTL">&bull; التهاب اللسان وجفاف الفم، التهاب الفم، اضطرابات في التذوق، فقدان الشهية،</p><p dir="RTL">&bull; التهاب البنكرياس، وهو قابل للشفاء بعد التوقف عن العلاج.</p><p dir="RTL">&bull; تغير في لون أو مظهر اللسان (قد يكون بسبب نمو الفطريات).</p><p dir="RTL"><strong>تأثيرات على الجلد والأغشية المخاطية</strong></p><p dir="RTL">&bull; هبات ساخنة مع احمرار في الوجه، حكة، طفح جلدي مصحوب أحياناً بحمى.</p><p dir="RTL">&bull; شرى (طفح جلدي مشابه لطفح القراص)، تورم تحسسي مفاجئ في الوجه والرقبة (وذمة وعائية)، صدمة تحسسية مهددة للحياة (انظر &quot;ما<br />&nbsp; عليك معرفته قبل تناول <strong>نيجازول</strong>&quot;)،</p><p dir="RTL">&bull; في حالات نادرة جداً، تم تسجيل حدوث طفح جلدي محمر منتشر على مساحات واسعة من الجسم مع ظهور بثور مصحوبة بحمى (بثار طفحي<br />&nbsp; معمم حاد) (انظر &quot;ما عليك معرفته قبل تناول <strong>نيجازول</strong>&quot;)،</p><p dir="RTL">&bull; طفح جلدي تقرحي متقشر على مساحات واسعة من الجسم ويكون مهدد للحياة (انحلال البشرة السمي التنخري، متلازمة<br />&nbsp; ستيفنز جونسون).</p><p dir="RTL">&bull; طفح دوائي ثابت: طفح جلدي على شكل بقع مستديرة حمراء مصحوباً بحكة، الشعور بحرقان تترك علامات ملونة وقد تعاود الظهور مرة<br />&nbsp; أخرى في نفس الأماكن إذا تم تكرار العلاج باستخدام نفس الدواء.</p><p dir="RTL"><strong>اضطرابات في الجهاز العصبي</strong></p><p dir="RTL">&bull; حدوث ضرر في أعصاب الأطراف (الاعتلال العصبي الحسي المحيطي) قد يسبب بعض التأثيرات على اليدين والقدمين مثل الوخز كوخز الإبر والدبابيس، الشعور بالبرد، تنميل، وانخفاض حاسة اللمس.</p><p dir="RTL">&bull; صداع،</p><p dir="RTL">&bull; دوخة،</p><p dir="RTL">&bull; نوبات،</p><p dir="RTL">&bull; ارتباك،</p><p dir="RTL">&bull; الاضطرابات العصبية، المعروفة باسم اعتلال الدماغ أو متلازمة المخيخ، ويشمل حدوث أعراض تشمل على ارتباك، اضطرابات في الوعي، &nbsp;&nbsp;<br />&nbsp;&nbsp; اضطرابات سلوكية، صعوبة تنسيق الحركات، مشاكل في النطق، اضطرابات المشي، حركات العين اللاإرادية، ارتعاش. يمكن أن تختفي هذه<br />&nbsp;&nbsp; الأعراض بشكل عام عند إيقاف العلاج وقد تترافق مع التغييرات في فحوصات التصوير بالرنين المغناطيسي. تم الإبلاغ عن حالات نادرة<br />&nbsp;&nbsp; جدًا من النتائج المميتة (انظر &quot;ما عليك معرفته قبل تناول <strong>نيجازول</strong>&quot;)،</p><p dir="RTL">&bull; التهاب السحايا غير البكتيري.</p><p dir="RTL"><strong>اضطرابات نفسية</strong></p><p dir="RTL">&bull; هلوسة،</p><p dir="RTL">&bull; اضطرابات عقلية (جنون العظمة، هذيان) التي قد تكون مصحوبة بأفكار أو أفعال انتحارية (انظر &quot;ما عليك معرفته قبل تناول<br />&nbsp;&nbsp;&nbsp;<strong>نيجازول</strong>&quot;)</p><p dir="RTL">&bull; الميل للاكتئاب.</p><p dir="RTL"><strong>اضطرابات في الرؤية</strong></p><p dir="RTL">&bull; اضطرابات مؤقتة في الرؤية على سبيل المثال عدم وضوح الرؤية، ازدواج في الرؤية، قصر النظر، انخفاض الرؤية، تغيرات في رؤية<br />&nbsp;&nbsp; الألوان،</p><p dir="RTL">&bull; تلف/التهاب العصب البصري.</p><p dir="RTL"><strong>اضطرابات في الدم</strong></p><p dir="RTL">&bull; انخفاض غير طبيعي في تعداد الصفائح الدموية، انخفاض غير طبيعي أو انخفاض كبير في عدد بعض خلايا الدم البيضاء (العدلات).</p><p dir="RTL"><strong>التأثيرات على الكبد</strong></p><p dir="RTL">&bull; ارتفاع إنزيمات الكبد (الترانزأميناز، الفوسفاتيز القلوي)،</p><p dir="RTL">&bull; حالات نادرة جداً من أمراض الكبد الخطيرة (مصحوبة في بعض الأحيان مع يرقان)، وبشكل خاص حالات فشل الكبد التي تتطلب عملية<br />&nbsp; زراعة الكبد.</p><p dir="RTL"><strong>تأثيرات</strong><strong> أخرى</strong></p><p dir="RTL">&bull; تغير لون البول إلى بول بني محمر اللون ناجم عن تناول الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>للإبلاغ عن حدوث أية تأثيرات جانبية</u></strong><strong><u>:</u></strong></p><p dir="RTL">يرجى منك إخبار طبيبك المعالج، الصيدلي الذي تتعامل معه أو الممرض، في حال حدوث أياً من التأثيرات الجانبية بما في ذلك أية تأثيرات جانبية يحتمل حدوثها ولم يتم ذكرها في هذه النشرة. كما يمكنك الإبلاغ عن التأثيرات الجانبية مباشرة عن طريق:</p><p dir="RTL"><strong>&bull;&nbsp; </strong><strong>المملكة العربية السعودية</strong><strong>:</strong></p><p dir="RTL"><strong>المركز الوطني للتيقظ الدوائي</strong><strong>:</strong></p><p dir="RTL">-&nbsp; <strong>رقم الفاكس: </strong>7662 - 205 - 11- 966 +</p><p dir="RTL">-&nbsp; <strong>مركز الاتصال الموحد: </strong>19999</p><p dir="RTL">-&nbsp; <strong>البريد الإلكتروني:</strong>&nbsp; npc.drug@sfda.gov.sa</p><p dir="RTL">-&nbsp; ا<strong>لموقع الإلكتروني:</strong> https://ade.sfda.gov.sa &nbsp;</p><p dir="RTL"><strong>&bull;&nbsp; </strong><strong>دول الخليج العربي الأخرى</strong><strong>:</strong></p><p dir="RTL"><strong>- </strong>الرجاء الاتصال بالجهات الوطنية في كل دولة.</p><p dir="RTL">إن تسجيل التأثيرات الجانبية يساعد في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; يُحفظ بعيداً عن متناول ومرأى الأطفال.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; يجب عدم تناول <strong>نيجازول</strong> بعد تاريخ انتهاء الصلاحية المذكور على العبوة والشريط. يشير تاريخ الانتهاء إلى آخر يوم من الشهرالمذكور.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; يحفظ في درجة حرارة أقل من 30 &ordm;م، في مكان جاف، بعيداً عن الضوء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; يجب عدم تناول <strong>نيجازول</strong> إذا لاحظت وجود علامات تلف واضحة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; يجب عدم التخلص من الأدوية عبر المياة المبتذلة (مياه الصرف الصحي) أو النفايات المنزلية. اسأل الصيدلي الذي تتعامل معه عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. ستساعد هذه الإجراءات على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي<strong> </strong>ميترونيدازول. يحتوي كل قرص ذي كسوة على 250 ملغم أو 500 ملغم من ميترونيدازول.</p><p dir="RTL">المواد الأخرى: لاكتوز أحادي الهيدرات، سليلوز دقيق البلورات، نشا الذرة، بريموجل، بي ڤي بي كي- 30 ، حمض السيتريك، ستيرات المغنيسيوم، هيبروميلوز وتلك.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تتوفر أقراص <strong>نيجازول</strong> المكسوة &nbsp;250 ملغم في عبوات تحتوي على 20 قرصاً وتحتوي العبوات المخصصة للمستشفيات على 100 أو 1000 قرصاً.</p><p dir="RTL">تتوفر أقراص <strong>نيجازول</strong> المكسوة 500 ملغم في عبوات تحتوي على 20 قرصاً وتحتوي العبوات المخصصة للمستشفيات على 100 أو 500 قرصاً.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>&quot;الخليج للصناعات الدوائية&quot; جلفار</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            13/11/2023م
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Negazole 500mg Film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains:  
Item no.	Material Name	Scale (mg/tab)
		
	Active Ingredient:	
1.		Metronidazole 	500.000
		
	Inactive Ingredients:	
1.		Lactose monohydrate*	70.000
2.		Microcrystalline cellulose (Avicel PH-102)	195.000
3.		Maize starch 	85.000
4.		Sodium starch glycolate (Primojel)	41.000
5.		Polyvinylpyrrolidone (PVP K-30)	42.000
6.		Stearic acid 	13.000
7.		Magnesium stearate 	4.000
8.		Absolute alcohol**	q.s. 
		
	Coating Materials:	
1.		Hydroxypropyl methylcellulose (Hypromellose)	12.000
2.		Talc fine powder 	8.000
3.		Purified water **	q.s.
Average weight of film coated tablet is: 970mg±3.0% (940.900mg-999.100mg)
Note:
* Quantity of Lactose monohydrate may required to adjust with quantity of 
     Metronidazole due to its potency calculation on 100% basis.
* * Evaporated during manufacturing process and does not appear in the final product.
For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-Coated Tablets
Description: White to off-white, oblong, biconvex, capsule shape film coated tablets.
Marking: Face one: embossed “N500”.
Face two: Plain.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The therapeutic indications of metronidazole are based on its antiparasitic and antibacterial activity and pharmacokinetic properties. They take into account both the clinical studies carried out with the medicinal product, and its position in the range of currently available anti-infectives.</p><p>Its use is limited to the treatment of infections caused by microorganisms which have been shown to be susceptible to the drug:</p><p>&bull; amebiasis,</p><p>&bull; urogenital trichomoniasis,</p><p>&bull; nonspecific vaginitis,</p><p>&bull; giardiasis,</p><p>&bull; curative treatment of medical and surgical infections caused by susceptible anaerobes,</p><p>&bull; replacement therapy after curative treatments given by injection of infections caused by<br />&nbsp;&nbsp; susceptible anaerobes.</p><p>Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Posology</strong></p><p>&bull;&nbsp; <u>Amebiasis</u></p><p>- Adults: 1.50 g/day as 3 divided doses.</p><p>- Children: 30 to 40 mg/kg/day as 3 divided doses.</p><p>In patients with amebic liver abscess, abscess drainage should be performed in conjunction with metronidazole therapy.</p><p>Treatment duration is 7 consecutive days.</p><p>&bull; <u>Trichomoniasis</u></p><p>&nbsp;&nbsp; In women (urethritis and vaginitis due to Trichomonas), treatment with a single<br />&nbsp;&nbsp; administration of a 2 g dose (4 tablets).</p><p>&nbsp;&nbsp; It is important that the partner be treated concomitantly, regardless of whether there are<br />&nbsp;&nbsp; clinical signs of Trichomonas vaginalis infestation, even without a positive laboratory test<br />&nbsp;&nbsp; result.</p><p>&bull; <u>Giardiasis</u></p><p>- Adults: 0.750 g to 1 g/day for 5 consecutive days.</p><p>- Children: From 10 to 15 years of age: 500 mg/day.</p><p>&bull; <u>Nonspecific vaginitis</u></p><p>&nbsp; 500 mg twice daily for 7 days.</p><p>&nbsp; The patient&rsquo;s partner should be treated at the same time.</p><p>&bull; <u>Treatment of infections caused by anaerobes (as first-line or replacement treatment) </u></p><p>- Adults: 1 g to 1.5 g/day.</p><p>- Children: 20 to 30 mg/kg/day.</p><p><strong>Method of administration:</strong></p><p>Oral use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                • Hypersensitivity to metronidazole or to imidazoles or to any of the excipients listed in 
   Section 6.1. 
• Children under 6 years of age because of the pharmaceutical form (see Section 4.4)



            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Hypersensitivity / Skin and appendages</u></strong></p><p>Allergic reactions, including anaphylactic shock, can occur and be life-threatening (see Section 4.8). In this case, treatment with metronidazole must be discontinued and appropriate medical treatment initiated.</p><p>If, at the start of treatment, patients experience generalized erythema with fever and pustules, acute generalized exanthematous pustulosis should be suspected (see Section 4.8). If this occurs, treatment must be discontinued and any further administration of metronidazole alone or in combination with other agents is contraindicated.</p><p>Severe skin reactions have been reported with metronidazole, such as Stevens-Johnson syndrome, toxic epidermal necrolysis, or Lyell syndrome) and acute generalized</p><p>exanthematous pustulosis. Patients must be informed of the signs and symptoms of these conditions and the skin should be closely monitored.</p><p>If any signs or symptoms of Stevens-Johnson syndrome, toxic epidermal necrolysis (e.g. progressive skin rash often with blisters or mucosal lesions) or acute generalized exanthematous pustulosis (see Section 4.8) occur, treatment must be discontinued and any&nbsp; further administration of metronidazole alone or in combination with other agents is contraindicated.&nbsp;</p><p><strong><u>Central nervous system</u></strong></p><p>If symptoms indicative of encephalopathy or cerebellar syndrome appear, patient management should be immediately reassessed and metronidazole treatment discontinued.</p><p>Cases of encephalopathy have been reported as part of post-marketing surveillance of the drug. Cases of MRI changes associated with encephalopathy have also been observed (see Section 4.8). Damage is most often located in the cerebellum (particularly in the dentate nucleus) and in the splenium of the corpus callosum. Most cases of encephalopathy and MRI changes are reversible on treatment discontinuation. Very rare cases of fatal outcome have been reported.</p><p>Patients should be monitored for warning signs of encephalopathy, and exacerbation of symptoms in patients with CNS disorders.</p><p>If aseptic meningitis occurs during treatment, rechallenge with metronidazole is not recommended, and an assessment of the benefit/risk ratio should be done for patients with serious infection.&nbsp;</p><p><strong><u>Peripheral nervous system</u></strong></p><p>Patients should be monitored for warning signs of peripheral neuropathy, particularly in long-term treatment or in patients with severe, chronic or progressive peripheral neurological disorders.</p><p>Psychiatric disorders</p><p>From administration of the first doses, patients may experience psychotic reactions, including self- endangering behavior, particularly if they have a history of psychiatric disorders (see Section 4.8). If this happens, metronidazole must be discontinued, the physician informed and appropriate therapeutic measures instituted immediately.&nbsp; <strong><u>Hematological effects</u></strong></p><p>In patients who have a history of hematological disorders or who are receiving high-dose and/or long- term treatment, regular blood tests, and particularly leukocyte counts, should be performed.</p><p>&nbsp;In patients with leukopenia, continued treatment will depend on how serious the infection is.</p><p><strong><u>Pediatric population</u></strong></p><p>Tablets are contraindicated in children under 6 years of age because of the risk of pulmonary aspiration. Other presentations of metronidazole-based medicinal products are available for young children.</p><p><strong>Interaction with other medicinal products</strong></p><p>Concomitant use of metronidazole and alcohol is not recommended (see Section 4.5).</p><p>Concomitant use of metronidazole and busulfan is not recommended (see Section 4.5).</p><p>Concomitant use of metronidazole and disulfiram is not recommended (see Section 4.5).</p><p><strong>Interactions with laboratory tests</strong></p><p>Metronidazole may immobilize treponemes, and thus lead to false positive results for the Nelson test.</p><p>Cases of severe hepatotoxicity/acute liver failure of very rapid onset after treatment initiation, including cases with fatal outcome, have occurred in patients with Cockayne syndrome who were administered medicinal products containing metronidazole intended for systemic use. In this population, metronidazole must therefore be used after thorough evaluation of the benefit/risk ratio and only if no alternative treatment is available. Liver function tests must be performed just before treatment initiation, during treatment and after treatment discontinuation, until liver function values are within the normal range, or until baseline values are reached. If the liver function test values markedly increase during treatment, the medicinal product should be discontinued.</p><p>Patients with Cockayne syndrome must be instructed to immediately report any symptoms of potential liver damage to their doctor and to stop taking metronidazole.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Antabuse reaction</strong></p><p>Many medicinal products trigger an antabuse effect with alcohol and their concomitant use with alcohol is not advisable.</p><p>Inadvisable combinations</p><p>&middot; Alcohol (beverage or excipient)</p><p>&nbsp; An antabuse effect (hot flushes, erythema, vomiting, tachycardia) may occur. Patients<br />&nbsp; should not consume alcoholic beverages or medicinal products containing alcohol.<br />&nbsp; Alcoholic beverages or medicinal products containing alcohol should not be ingested<br />&nbsp; again until medicinal products have been completely eliminated from the body. The<br />&nbsp; half-life should be used as a reference.</p><p>&middot; Busulfan</p><p>&nbsp; When co-administered with high busulfan doses, metronidazole causes a two-fold<br />&nbsp; increase in plasma busulfan concentrations.</p><p>&middot; Disulfiram</p><p>&nbsp; There is a risk of acute psychotic episodes or confusion, reversible on discontinuation of<br />&nbsp; the drug combination.</p><p>&nbsp;&nbsp;Combinations requiring precautions for use</p><p>&middot; Enzyme-inducing anticonvulsants</p><p>&nbsp; Decreased plasma concentrations of metronidazole can occur due to increased liver &nbsp;&nbsp;<br />&nbsp; metabolism by the inducer.</p><p>&nbsp; Clinical monitoring is required and the metronidazole dose may need to be adjusted<br />&nbsp; during and after treatment with the inducer.</p><p>&middot; Rifampicin</p><p>&nbsp; Decreased plasma concentrations of metronidazole can occur due to increased liver<br />&nbsp; metabolism by rifampicin.</p><p>&nbsp; Clinical monitoring is required and the metronidazole dose may need to be adjusted &nbsp;<br />&nbsp; during and after treatment with rifampicin.</p><p>&middot; Lithium</p><p>&nbsp;&nbsp; Increased blood lithium levels can occur, which can reach toxic levels with signs of<br />&nbsp;&nbsp; lithium overdose. Strict monitoring of blood lithium levels should be performed and the<br />&nbsp;&nbsp; lithium dose adjusted if necessary.</p><p>&nbsp; Combinations to be taken into consideration</p><p>&middot; Fluorouracil (and by extrapolation, tegafur and capecitabine) Increased fluorouracil toxicity can occur due to decreased clearance.&nbsp;</p><p>&middot; Specific issue: INR imbalance</p><p>&nbsp; Numerous cases of increased oral anticoagulant activity have been reported in patients<br />&nbsp; receiving antibiotics. The severity of the infection or inflammation, age and general<br />&nbsp; health status of the patient appear to be risk factors. Under these circumstances, it seems &nbsp;&nbsp;<br />&nbsp; difficult to determine to what extent the infection itself or its treatment play a role in the<br />&nbsp; INR imbalance. However, certain classes of antibiotics are more involved, particularly<br />&nbsp; fluoroquinolones, macrolides, cyclines, cotrimoxazole and certain cephalosporins.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy</strong></p><p>There is no evidence from animal studies that metronidazole is teratogenic. Therefore, no malformative effect is expected in humans. To date, substances causing malformations in humans have been shown to be teratogenic in animals during well-conducted studies in two species.</p><p>In man, analysis of a large number of exposed pregnancies did not seem to show any particular teratogenic or fetotoxic effects of metronidazole.</p><p>However, only epidemiological studies would make it possible to rule out any risk. Therefore, metronidazole may be prescribed during pregnancy if necessary.&nbsp;</p><p><strong>Lactation</strong></p><p>Since metronidazole is excreted in breast milk, administration should be avoided in breast-feeding women</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients should be warned of the potential risk of dizziness, confusion, hallucinations and seizures or vision disorders, and should be advised not to drive or operate machines if they experience such symptoms.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Blood and lymphatic system disorders</strong></p><p>&nbsp;&bull; neutropenia, agranulocytosis, thrombocytopenia.</p><p><strong>Psychiatric disorders</strong></p><p>&nbsp;&bull; hallucinations,</p><p>&nbsp;&bull; psychotic reactions with paranoia and/or delirium possibly accompanied by suicidal<br />&nbsp;&nbsp;&nbsp; ideation or suicide attempts in some isolated cases (see Section 4.4),</p><p>&nbsp;&bull; depressed mood.</p><p><strong>Nervous system disorders</strong></p><p>&nbsp;&bull; peripheral sensory neuropathy,</p><p>&nbsp;&bull; headache,</p><p>&nbsp;&bull; dizziness,</p><p>&nbsp;&bull; confusion,</p><p>&nbsp;&bull; seizures,</p><p>&nbsp;&bull; encephalopathy that may be associated with MRI changes, generally reversible upon<br />&nbsp;&nbsp;&nbsp; treatment discontinuation. Very rare cases of fatal outcome have been reported (see<br />&nbsp;&nbsp;&nbsp; Section 4.4),</p><p>&nbsp;&bull; sub-acute cerebellar syndrome (ataxia, dysarthria, gait disorders, nystagmus, tremor)<br />&nbsp; &nbsp;&nbsp;(see Section 4.4),</p><p>&nbsp;&bull; aseptic meningitis (see Section 4.4).</p><p><strong>&nbsp;Eye disorders</strong></p><p>&nbsp;&bull; transient vision disorders such as blurred vision, diplopia, myopia, reduced visual<br />&nbsp;&nbsp;&nbsp; acuity, impaired color vision,</p><p>&nbsp;&bull; neuropathy / optic neuritis.&nbsp;</p><p><strong>Gastrointestinal disorders</strong></p><p>&nbsp;&bull; minor gastrointestinal disorders (epigastric pain, nausea, vomiting, diarrhea),</p><p>&nbsp;&bull; glossitis with dry mouth, stomatitis, taste disorders, anorexia,</p><p>&nbsp;&bull; pancreatitis, reversible on treatment discontinuation,</p><p>&nbsp;&bull; discoloration or change in the appearance of the tongue (mycosis).&nbsp;</p><p><strong>Hepatobiliary disorders</strong></p><p>&nbsp;&bull; elevated liver enzyme levels (AST, ALT, alkaline phosphatase), very rare cases of<br />&nbsp;&nbsp;&nbsp; acute cholestatic or mixed hepatitis and hepatocellular liver injury, sometimes with<br />&nbsp;&nbsp;&nbsp; jaundice, have been reported. Isolated cases of hepatocellular insufficiency possibly<br />&nbsp;&nbsp; requiring liver transplantation have been reported.</p><p><strong>Skin and subcutaneous tissue disorders</strong></p><p>&nbsp;&bull; hot flushes, pruritus, skin rash occasionally with fever,</p><p>&nbsp;&bull; urticaria, angioedema, anaphylactic shock (see Section 4.4),</p><p>&nbsp;&bull; very rare cases of acute generalized exanthematous pustulosis (see Section 4.4),</p><p>&nbsp;&bull; toxic epidermal necrolysis,</p><p>&nbsp;&bull; Stevens-Johnson syndrome,</p><p>&nbsp;&bull; fixed drug eruption.</p><p><strong>&nbsp;Other effects</strong></p><p>&nbsp;&bull; urine can appear reddish-brown as water-soluble pigments may be found due to<br />&nbsp;&nbsp;&nbsp; metabolism of the drug.</p><p><strong><u>Healthcare professionals are asked to report any suspected adverse reactions via: </u></strong></p><p><strong>&bull; Saudi Arabia: </strong></p><p><strong>The National Pharmacovigilance Centre (NPC): </strong></p><p><strong>- Fax: </strong>+966-11-205-7662</p><p><strong>- SFDA Call Centre: </strong>19999</p><p><strong>- E-mail: </strong>npc.drug@sfda.gov.sa</p><p><strong>- Website: </strong>https://ade.sfda.gov.sa</p><p><strong>&bull; Other GCC States: </strong></p><p>- Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Administration of up to 12 g as a single dose has been reported in cases of attempted suicide and accidental overdose.</p><p>The symptoms were limited to vomiting, ataxia and mild disorientation. There is no specific antidote to metronidazole overdose. If massive overdose occurs, symptomatic treatment should be instituted.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacotherapeutic group</strong>: antibacterial, antiparasitic antibiotics belonging to the 5-nitroimidazole group, ATC code: J01XD01 &mdash; P01AB01 (J: Anti infectives for systemic use, other antibacterials - imidazole derivatives - P: Antiprotozoals, agents against amebiasis and other protozoal diseases - nitroimidazole derivatives).</p><p>The MIC breakpoints differentiating susceptible from intermediate strains, and intermediate from resistant strains are as follows: S &le; 4 mg/L and R &gt; 4 mg/L.</p><p>The prevalence of acquired resistance in certain species can vary geographically and over time. It is therefore useful to have local information on the prevalence of resistance, especially in treating severe infections. These data are only guidelines indicating the probability of susceptibility of a bacterial strain to this antibiotic.</p><p>When the variability of prevalence of resistance of a bacterial species is known in France, it is indicated in the table below:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Category</strong></p></td><td style="vertical-align:top"><p><strong>Prevalence of acquired resistance in France (&gt;10%) (range)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong><u>Susceptible species</u></strong></p><p><strong>Gram-negative aerobes</strong></p><p>Helicobacter pylori</p><p>&nbsp;</p><p><strong>Anaerobes</strong></p><p>Bacteroides fragilis</p><p>Bifidobacterium&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>Bilophila</p><p>Clostridium</p><p>Clostridium difficile</p><p>Clostridium perfringens</p><p>Eubacterium</p><p>Fusobacterium</p><p>Peptostreptococcus</p><p>Porphyromonas</p><p>Prevotella</p><p>Veillonella&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>30%</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>60-70%</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>20-30%</p></td></tr><tr><td style="vertical-align:top"><p><strong><u>Resistant species</u></strong></p><p><strong>Gram-positive aerobes</strong></p><p>Actinomyces</p><p>&nbsp;</p><p><strong>Anaerobes</strong></p><p>Mobiluncus</p><p>Propionibacterium acnes</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong><u>Antiparasitic activity</u></strong></p><p>Entamoeba histolytica</p><p>Giardia intestinalis</p><p>Trichomonas vaginalis</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Absorption </strong></p><p>Following oral administration, metronidazole is rapidly absorbed (at least 80% within one hour). Peak plasma concentrations obtained after oral administration are similar to those obtained after IV administration of equivalent doses. Oral bioavailability is 100%. It is not significantly affected by concomitant intake of food.</p><p><strong>Distribution</strong></p><p>&bull; Approximately one hour after a single 500 mg dose, the mean peak plasma<br />&nbsp;&nbsp;&nbsp; concentration is 10 micrograms/mL. After 3 hours, the mean plasma concentration is<br />&nbsp;&nbsp;&nbsp; 13.5 micrograms/mL.</p><p>&bull; The plasma half-life is from 8 to 10 hours.</p><p>&bull; The drug is poorly bound to plasma protein, i.e. below 20%.</p><p>&bull; The apparent volume of distribution is high (approximately 40 L, i.e. 0.65 L/kg).</p><p>&bull; The drug is rapidly and widely distributed, with concentrations close to plasma<br />&nbsp;&nbsp; concentrations, in the lungs, kidneys, liver, skin, bile, CSF, saliva, semen and vaginal<br />&nbsp;&nbsp; secretions. Metronidazole crosses the placental barrier and is excreted in breast milk. <strong>Metabolism</strong></p><p>Metabolism is mainly hepatic. Two main compounds are formed by oxidation:</p><p>&bull; the &#39;alcohol&#39; metabolite (major metabolite) with antibacterial activity against anaerobes<br />&nbsp;&nbsp; that is approximately 30% that of metronidazole, and an elimination half-life of<br />&nbsp;&nbsp; approximately 11 hours;</p><p>&bull; the &#39;acid&#39; metabolite, in small amounts, with a bactericidal activity of approximately 5%<br />&nbsp; that of metronidazole.</p><p><strong>Excretion </strong></p><p>High concentrations of metronidazole can be found in the liver and bile. Low concentrations of the drug are found in the colon. Metronidazole is poorly excreted in the feces. It is mainly eliminated in the urine since metronidazole and its oxidized metabolites, eliminated in the urine, account for approximately 35 to 65% of the administered dose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="0" cellpadding="0" style="width:522px"><tbody><tr><td style="vertical-align:top"><p><strong><u>Inactive Ingredients:</u></strong></p></td></tr><tr><td style="vertical-align:top"><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lactose monohydrate*</p></td></tr><tr><td style="vertical-align:top"><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Microcrystalline cellulose (Avicel PH-102)</p></td></tr><tr><td style="vertical-align:top"><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Maize starch</p></td></tr><tr><td style="vertical-align:top"><p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sodium starch glycolate (Primojel)</p></td></tr><tr><td style="vertical-align:top"><p>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Polyvinylpyrrolidone (PVP K-30)</p></td></tr><tr><td style="vertical-align:top"><p>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stearic acid</p></td></tr><tr><td style="vertical-align:top"><p>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Magnesium stearate</p></td></tr><tr><td style="vertical-align:top"><p>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Absolute alcohol**</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong><u>Coating Materials:</u></strong></p></td></tr><tr><td style="vertical-align:top"><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hydroxypropyl methylcellulose (Hypromellose)</p></td></tr><tr><td style="vertical-align:top"><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Talc fine powder</p></td></tr><tr><td style="vertical-align:top"><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Purified water *<strong>*</strong></p><p>&nbsp;</p><p>* Quantity of Lactose monohydrate may required to adjust with quantity of<br />&nbsp;&nbsp;&nbsp;&nbsp; Metronidazole due to its potency calculation on 100% basis.</p><p><strong>** </strong>Evaporated during manufacturing process and does not appear in the final product.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months from the date of manufacturing
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C, in a dry place, protected from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>10 tablets in Aluminium-PVC/PVDC blister, 2 blisters packed in a printed carton along with a leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Gulf Pharmaceutical Industries - Julphar
Digdaga, Airport Street
Ras Al Khaimah - United Arab Emirates
P.O. Box 997
Tel. No.:   (9717) 2 461 461
Fax No.:   (9717) 2 462 462

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                13. November. 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>